PROMIS NEUROSCIENCES INC (PMN)
CA74346M4065 - Common Stock
ProMIS Neurosciences Issues Letter to Shareholders
ProMIS Neurosciences Issues Letter to Shareholders
CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company...
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310...
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology...
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of...
Wednesday 9/25 Insider Buying Report: PMN, BHVN
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the second quarter of 2024.
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ProMIS Neurosciences (NASDAQ:PMN) just reported results for the second quarter ...
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential...
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent...
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder...
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024.
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024...
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies...